8-K: SeaStar Medical AKI Trial Continues, Enrollment Boosted

SeaStar Medical's pivotal NEUTRALIZE-AKI trial for its Selective Cytopheretic Device (SCD) therapy will continue, with an increased patient enrollment target to strengthen statistical power.

Summary

• The independent Data Safety Monitoring Review Board (DSMB) recommended the continuation of the NEUTRALIZE-AKI pivotal trial for the Selective Cytopheretic Device (SCD) therapy in adult patients with acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT).
• The DSMB reported zero device-related safety issues during the interim analysis of the first 100 patients enrolled.
• A signal of potential clinical benefit was observed in the treatment group across key study outcome measures.
• To strengthen the statistical power of the study, the DSMB recommended increasing the total patient enrollment from 200 to 339 patients.
• Patient enrollment is now estimated to be complete near the end of 2026, extending the trial timeline.
• SeaStar Medical's QUELIMMUNE (SCD-PED) therapy, approved in 2024 for pediatric AKI, has shown positive preliminary results in the SAVE Surveillance Registry, with no device-related safety events and 75% patient survival through 28 days among the first 20 pediatric patients.

Sentiment

Score: 7

Explanation: The sentiment is largely positive due to the DSMB's recommendation to continue the pivotal trial, the absence of device-related safety issues, and the observed signal of potential clinical benefit. The positive preliminary results from the pediatric registry also contribute. However, the extended trial timeline and the explicit mention of needing to secure future capital introduce some caution, preventing a higher score.

Positives

• The independent DSMB recommended the continuation of the NEUTRALIZE-AKI pivotal trial, indicating no fundamental issues with the therapy or trial design.
• Zero device-related safety issues were reported, consistent with previous safety profiles and preliminary pediatric registry results.
• A signal of potential clinical benefit was observed in the treatment group, suggesting the therapy's efficacy.
• The increase in sample size is intended to strengthen the statistical power, providing greater confidence in future results.
• The QUELIMMUNE (SCD-PED) therapy, already FDA approved for pediatric AKI, is showing positive preliminary commercial results with 75% survival through 28 days and no device-related safety events in the SAVE Surveillance Registry.

Negatives

• The trial timeline will be extended due to the increased patient enrollment target from 200 to 339 patients.
• Patient enrollment is now estimated to be complete near the end of 2026, which is a delay compared to the original implied timeline for 200 patients.

Risks

• Risk that SeaStar Medical may not be able to obtain regulatory approval of its SCD product candidates.
• Risk that SeaStar Medical may not be able to raise sufficient capital to fund its operations, including current or future clinical trials.
• Risk that SeaStar Medical and its collaborators are unable to successfully develop and commercialize its products or services, or experience significant delays.
• Risk that SeaStar Medical may never achieve or sustain profitability.
• Risk that SeaStar Medical may not be able to secure additional financing on acceptable terms.
• Risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations.
• Risk of product liability or regulatory lawsuits or proceedings relating to SeaStar Medical's products and services.
• Risk that SeaStar Medical is unable to secure or protect its intellectual property.

Future Outlook

SeaStar Medical intends to continue driving shareholder value through successful execution of QUELIMMUNE commercial efforts and the completion of the NEUTRALIZE-AKI trial, leading to potential filing and approval of the SCD therapy in adult AKI. The company will also monitor options to secure future sources of capital as needed to support future milestones.

Management Comments

• Kevin Chung, MD, Chief Medical Officer: "We are encouraged by the DSMBs recommendation, which reinforces the overall safety profile of our SCD therapy and suggests a potential clinical benefit, which we are observing in the commercial setting with QUELIMMUNE in the pediatric population."
• Kevin Chung, MD, Chief Medical Officer: "Sample size re-estimations are well established practices in pivotal trials, and while an upward re-estimation will extend the trial timeline, we are optimistic it will strengthen the statistical power and provide critical care teams with greater confidence in the results."
• Eric Schlorff, CEO: "The DSMBs recommendation reinforces our confidence in advancing the NEUTRALIZE-AKI trial and our mission to deliver a first-in-class therapy that can change outcomes for these critically ill patients."
• Eric Schlorff, CEO: "We intend to continue to drive shareholder value through successful execution of our QUELIMMUNE commercial efforts and the completion of the NEUTRALIZE-AKI trial and the potential filing and approval of the SCD therapy in adult AKI. We have been prudently managing our financial resources and will continue to monitor our options to secure future sources of capital, as needed, to support the achievement of our future milestones."

Industry Context

Acute Kidney Injury (AKI) is a severe condition characterized by sudden kidney function loss, often caused by sepsis, trauma, or COVID-19. It leads to destructive hyperinflammation and can progress to multi-organ dysfunction or failure, with no FDA-approved disease-modifying therapy available despite the use of CRRT for severe cases. The SCD therapy aims to address this unmet medical need by neutralizing over-active immune cells and stopping the cytokine storm.

Comparison to Industry Standards

• The QUELIMMUNE SAVE Surveillance Registry for pediatric AKI patients reported 75% survival through 28 days with no device-related safety events among the first 20 patients. These data are on track to validate or potentially exceed a 50% reduction in loss of life compared to historical data, as reported in Kidney Medicine.

Stakeholder Impact

• Shareholders: Potential for long-term value creation if the trial is successful, but also faces extended timelines and potential dilution from future capital raises.
• Patients with AKI: Continued hope for a novel, disease-modifying therapy for a life-threatening condition with no current effective treatment options.
• Employees: Continued work on the pivotal trial and commercialization efforts, supporting job stability and company growth.
• Healthcare providers: Potential for a new therapeutic option to improve outcomes for critically ill AKI patients.

Next Steps

• Accelerate patient enrollment for the NEUTRALIZE-AKI pivotal trial to meet the new target of 339 patients.
• Complete patient enrollment for the NEUTRALIZE-AKI trial near the end of 2026.
• Continue successful execution of QUELIMMUNE commercial efforts.
• Monitor options to secure future sources of capital as needed to support future milestones.
• Potential filing and approval of the SCD therapy in adult AKI following trial completion.

Key Dates

Recommendation

The independent DSMB's recommendation to continue the NEUTRALIZE-AKI pivotal trial, citing zero device-related safety issues and a signal of potential clinical benefit, is a significant positive development. This reinforces confidence in the Selective Cytopheretic Device (SCD) therapy. However, the decision to increase patient enrollment from 200 to 339 will extend the trial timeline, with enrollment now estimated to be complete near the end of 2026. This delay, coupled with management's statement about monitoring options to secure future capital, introduces uncertainty regarding funding and the time to market for the adult AKI indication. While the long-term potential remains, the near-term challenges warrant a cautious 'hold' stance until more clarity emerges on funding and the revised trial timeline's impact.

Keywords

Acute Kidney Injury, AKI, Selective Cytopheretic Device, SCD, NEUTRALIZE-AKI, Clinical Trial, DSMB, CRRT, QUELIMMUNE, Sepsis, Hyperinflammation, Medical Device, FDA Approval